EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Antifungal Susceptibility of Clinical Meyerozyma guillermondii Isolates Obtained Between 1994 and 2014: Original Research and Comparison with Published Data

Aleksandra Górzyńska, Daria Konarska iD, Agnieszka Korzeniowska-Kowal, Anna Wzorek, Bartosz Pencakowski, Urszula Nawrot iD

Pathogens · 2026

DOI: 10.3390/pathogens15020235 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pathogens, 2026. Verfasst von Aleksandra Górzyńska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Microbiology and Parasitology, Wrocław Medical University, Borowska 211a, 50-556 Wrocław, Poland. Hauptthemen laut MEDLINE: Antifungal Agents, Saccharomycetales, Mycoses. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wroclaw Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

Meyerozyma guilliermondii is a yeast species widely distributed in the natural environment and one of the rare emerging pathogens capable of causing difficult to treat, severe infections. The species’ susceptibility profile is not fully defined; however, the species could be more prone to develop resistance than other Candida species. The objective of this research was to determine the susceptibility of a local collection of Meyerozyma guilliermondii clinical isolates to classical antifungal drugs as well as a new one—manogepix. (2)

Methods

The study included 20 clinical isolates identified using the MALDI–TOF method followed with sequencing of ITS1-2 region of DNA. Overall, the susceptibility to 12 antifungal drugs was tested. Nine drugs (amphotericin B, flucytosine, fluconazole, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, and micafungin) were assessed using the MICRONAUT–AT test. The susceptibility to the new drug, manogepix, as well as isavuconazole, clotrimazole and anidulafungin, was determined using the microdilution method recommended by EUCAST. Additionally, anidulafungin and voriconazole MIC was also examined with commercial gradient tests. (3)

Results

Overall, the isolates showed low MIC values for amphotericin B (0.125 to 1 mg/L) and for flucytosine (≤0.06 to 32 mg/L), with the exception of one isolate with a high MIC value. The MIC ranges for azoles were 2–64 mg/L (fluconazole), 0.008–0.5 mg/L (voriconazole), ≤0.03–≥4 mg/L (itraconazole) and 0.008–0.5 mg/L (posaconazole). One isolate showed non-WT phenotype to all tested azoles. For anidulafungin, the MIC values ranged from ≤0.06 to 0.25 mg/L; however, in the reference method, higher values were observed, but they did not exceed 2 mg/L (ECOFF value). For manogepix, the MIC values ranged from 0.002 to 0.125 mg/L. Finally, the comparison of the obtained and published susceptibility data was conducted. (4)

Conclusions

The data obtained in this study are consistent with reports by other authors and indicate that resistance to azoles or 5-fluorocytosine among clinical isolates of Meyerozyma guilliermondii should be considered. The low MIC values of manogepix suggest the potentially good efficacy of this drug against Meyerozyma guilliermondii species.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsSaccharomycetalesMycosesMicrobial Sensitivity TestsHumansDrug Resistance, FungalSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationDNA, FungalSequence Analysis, DNAFlucytosineDNA, Ribosomal Spacer

Stichwörter der Autor:innen

Meyerozyma guillermondiiamphotericin Bazolesechinocandinsflucytosinemanogepix

Substanzen

Antifungal AgentsDNA, FungalFlucytosineDNA, Ribosomal Spacer

Autor:innen und Institutionen

  • Department of Pharmaceutical Microbiology and Parasitology, Wrocław Medical University, Borowska 211a, 50-556 Wrocław, Poland.
  • Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, St. Weigla 12, 53-114 Wrocław, Poland.
  • Department of Pharmaceutical Biology and Biotechnology, Wrocław Medical University, 50-556 Wrocław, Poland.

ORCID-Profile: Daria Konarska, Urszula Nawrot

Förderung

  • Wroclaw Medical University

Zitieren

APA

Górzyńska, A., Konarska, D., Korzeniowska-Kowal, A., Wzorek, A., Pencakowski, B., & Nawrot, U. (2026). Antifungal Susceptibility of Clinical Meyerozyma guillermondii Isolates Obtained Between 1994 and 2014: Original Research and Comparison with Published Data. Pathogens. https://doi.org/10.3390/pathogens15020235

Vancouver

Górzyńska A, Konarska D, Korzeniowska-Kowal A, Wzorek A, Pencakowski B, Nawrot U. Antifungal Susceptibility of Clinical Meyerozyma guillermondii Isolates Obtained Between 1994 and 2014: Original Research and Comparison with Published Data. Pathogens. 2026. doi:10.3390/pathogens15020235

BibTeX
@article{Grzyska2026,
  author = {Górzyńska, Aleksandra and Konarska, Daria and Korzeniowska-Kowal, Agnieszka and Wzorek, Anna and Pencakowski, Bartosz and Nawrot, Urszula},
  title = {Antifungal Susceptibility of Clinical Meyerozyma guillermondii Isolates Obtained Between 1994 and 2014: Original Research and Comparison with Published Data},
  journal = {Pathogens},
  year = {2026},
  doi = {10.3390/pathogens15020235}
}
Kostenlos starten →